Multi-source data-driven machine learning reshapes the diagnosis and treatment of lung cancer
Peer-Reviewed Publication
Updates every hour. Last Updated: 23-Oct-2026 07:16 ET (23-Oct-2026 11:16 GMT/UTC)
This review explores how multi-source data-driven machine learning is transforming lung cancer care, from early screening and diagnosis to personalized treatment and prognosis. It examines imaging, multi-omics, liquid biopsy, pathology, and clinical data, alongside traditional and advanced machine learning approaches. By linking data characteristics with model selection and clinical applications, the review highlights opportunities for precision medicine while addressing challenges in data standardization, multimodal integration, interpretability, and effective clinical translation.
A recent review reveals how aberrantly reprogrammed purine metabolism acts as a critical driver of tumor progression and therapy resistance. By comprehensively mapping the regulatory networks of key metabolic enzymes and their inhibitors, the study highlights the selective targeting of purine metabolism networks as a powerful next-generation anticancer strategy.
For sleep-deprived nursing moms, artificial intelligence may feel like a lifeline. In fact, a new national survey from Orlando Health reveals if women ages 18 to 44 had an urgent breastfeeding question or concern half (51%) of them would first turn to an AI chatbot, social media or a search engine.
Biologic medicines have transformed the treatment of cancer, autoimmune diseases, migraine, inflammatory disorders and many other diseases. Yet, their growing use among women of reproductive age constitutes a major clinical challenge in that therapeutic IgG antibodies are actively transported across the placenta to the developing fetus. Evidence that supports safe use of such therapeutics during pregnancy remains limited.
Now, researchers from the University of Oslo and Oslo University Hospital, together with national and international collaborators, have uncovered that the placenta distinguishes between antibodies and albumin, a finding that may reshape the future design of biologic medicines with reduced fetal exposure.
MIT researchers showed that blocking caspase-1, an enzyme involved in lung inflammation, appears to reduce the risk of developing tumors. The enzyme-blocking drug might help prevent lung cancer in people at high risk for the disease.